Budesonide (Jorveza®). HTA ID: 24014

Assessment Status Rapid Review complete
HTA ID 24014
Drug Budesonide
Brand Jorveza®
Indication For the treatment of eosinophilic oesophagitis in adults (older than 18 years of age).
Assessment Process
Rapid review commissioned 15/05/2024
Rapid review completed 07/06/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of budesonide compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.